RPG Life Sciences Peer Comparison
NSE: RPGLIFE | BSE: 532983
₹2,530.50
₹-45.20
(-1.75%)
As on 02-Nov-2026 11:59IST
Market cap
₹4,174 Cr
Revenue (TTM)
₹764 Cr
P/E Ratio
38.2
P/B Ratio
6.1
Div. Yield
0.9 %
Edit
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
4,174 | 17,720 | 12,449 | 12,231 | 5,921 |
Revenue (₹ Cr) |
764 | 2,684 | 1,170 | 710 | 2,286 |
Net Profit (₹ Cr) |
111.01 | 669.74 | 279.64 | 188.64 | 188.43 |
Net Margin (%) |
14.07 | 24.24 | 22.94 | 25.69 | 8.15 |
RoE (%) |
17.79 | 19.79 | 13.92 | 20.46 | 14.35 |
Price to Earnings |
38.15 | 26.46 | 44.08 | 64.94 | 31.40 |
Price-To-Book |
6.07 | 4.88 | 6.00 | 12.78 | 4.29 |
Income Statement (₹ Cr)
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Operating Revenue
|
746.00 | 2,684.41 | 1,170.41 | 709.64 | 2,285.51 |
|
Total Income
|
769.70 | 2,763.43 | 1,218.73 | 734.34 | 2,311.65 |
|
Total Expenditure
|
597.14 | 1,761.70 | 766.14 | 458.93 | 2,009.09 |
|
EBITDA
|
148.86 | 922.70 | 404.27 | 250.72 | 276.42 |
|
Depreciation
|
22.58 | 82.27 | 74.77 | 17.12 | 34.55 |
|
EBIT
|
126.28 | 840.44 | 329.50 | 233.59 | 241.87 |
|
Interest
|
2.05 | 5.42 | 0.24 | 8.49 | 18.23 |
|
Other Income
|
23.70 | 79.02 | 48.32 | 24.69 | 26.14 |
|
Exceptional Items
|
-7.32 | -25.66 | -3.28 | 0.00 | 0.00 |
|
Profit before Tax
|
140.61 | 888.39 | 374.31 | 249.79 | 249.78 |
|
Provision for Tax
|
34.72 | 218.65 | 94.68 | 61.16 | 61.34 |
|
Profit after Tax
|
105.89 | 669.74 | 279.64 | 188.64 | 188.43 |
Liabilities (₹ Cr)
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
619.24 | 3,631.29 | 2,075.76 | 957.32 | 1,381.13 |
|
Minority Interest
|
0.00 | 0.00 | 3.07 | -0.30 | 0.05 |
|
Non-Current Liabilities
|
15.95 | 146.95 | 53.38 | 106.92 | 198.11 |
|
Current Liabilities
|
140.19 | 563.70 | 201.71 | 248.88 | 725.93 |
|
Total Liabilities
|
-- | 4,157.10 | 2,231.79 | 1,174.38 | 1,936.12 |
Assets (₹ Cr)
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
289.88 | 1,454.42 | 980.16 | 534.87 | 689.62 |
|
Current Assets
|
473.90 | 2,864.85 | 1,290.68 | 723.33 | 1,439.96 |
|
Total Assets
|
-- | 4,157.10 | 2,231.79 | 1,174.38 | 1,936.12 |
|
Total Debt*
|
-- | 0.00 | 0.00 | 148.29 | 194.69 |
|
Net Current Assets
|
333.71 | 2,301.15 | 1,088.97 | 474.44 | 714.03 |
|
Contingent Liabilities
|
-- | 4.82 | 3.76 | -- | 335.40 |
Cashflow (₹ Cr)
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-- | 565.41 | 266.88 | 69.55 | 32.64 |
|
Cash Flow from Investing Activities
|
-- | -570.15 | -142.72 | -330.93 | -123.42 |
|
Cash from Financing Activities
|
-- | -64.34 | -112.88 | 247.29 | 97.40 |
|
Net Cash Inflow / Outflow
|
-- | -69.08 | 11.28 | -14.09 | 6.62 |
Ratios
Profitability Ratios
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | 24.61 | 18.04 | 28.50 | 10.19 |
|
ROE (%)
|
18.21 | 19.79 | 13.92 | 20.46 | 14.35 |
|
ROA (%)
|
14.30 | 16.78 | 12.86 | 16.29 | 9.32 |
|
EBIT Margin (%)
|
16.93 | 31.31 | 28.15 | 32.92 | 10.58 |
|
Net Margin (%)
|
13.76 | 24.24 | 22.94 | 25.69 | 8.15 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
11.94 | 8.19 | 4.02 | 26.57 | 30.20 |
|
EBIT Growth (%)
|
-1.31 | 24.77 | -11.95 | 26.37 | 164.21 |
|
Net Profit Growth (%)
|
-50.84 | 26.27 | -12.44 | 24.97 | 89.48 |
|
EPS Growth (%)
|
0.01 | 29.79 | -12.06 | 8.48 | 149.66 |
|
Book Value Growth (%)
|
-- | 18.43 | 11.27 | 79.97 | 7.80 |
Valuation Ratios
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Price / Earnings
|
38.17 | 25.07 | 45.73 | 63.97 | 33.04 |
|
Price / Book Value
|
6.87 | 4.77 | 6.28 | 12.59 | 4.51 |
|
Dividend Yield (%)
|
0.93 | 0.36 | 0.61 | 0.14 | 0.18 |
|
EV/EBITDA
|
26.86 | 17.91 | 31.20 | 48.19 | 22.91 |
|
Market Cap (₹ Cr)
|
-- | 11,956.86 | 10,627.92 | 6,690.53 | 1,851.92 |
Solvency Ratios
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.07 | 0.09 |
|
Short term debt to equity ratio
|
-- | -- | -- | 0.12 | 0.03 |
|
Current Ratio
|
3.38 | 5.08 | 6.40 | 2.91 | 1.98 |
|
Quick Ratio
|
2.52 | 3.69 | 4.43 | 1.80 | 1.54 |
|
Interest Coverage
|
69.59 | 165.03 | 1,593.82 | 30.42 | 14.70 |
Operating Efficiency Ratios
| RPG Life Sciences | Alivus Life Sciences | Concord Biotech | Sudeep Pharma | Morepen Lab | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.58 | 36.81 | 35.24 | 34.68 | 15.07 |
|
Asset Turnover
|
1.01 | 0.67 | 0.54 | 0.61 | 1.13 |
|
Receivable days
|
-- | 144.58 | 169.86 | 115.16 | 66.49 |
|
Inventory Days
|
-- | 96.67 | 97.92 | 96.15 | 57.79 |
|
Payable days
|
-- | 135.45 | 159.68 | 106.08 | 116.46 |
|
Cash Conversion Cycle
|
-- | 105.80 | 108.11 | 105.23 | 7.82 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
